Article

Quiz: Which RA drug has the least negative impact on bone mineral density?

Author(s):

Ingrid Torjesen

Patients with rheumatoid arthritis are at increased risk for osteoporosis. This heightened risk of osteoporosis can be due to a combination of factors: inactivity due to the pain and loss of joint function associated with the disease, a direct the rheumatoid arthritis disease process, and their treatment for rheumatoid arthritis. In this quiz, test your knowledge on the risk of osteoporosis in rheumatoid arthritis and how it should be treated.

Which of the following factors do not increase the risk of osteoporosis in patients with rheumatoid arthritis?

a) Female sex

b) Post-menopause

c) Low BMI

d) Elderly

e) Lack of vitamin D

f) Smoking

g) Drinking alcohol

h) Anemia


Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Related Content
Laure Gossec, MD, PhD, Professor of Rheumatology, Pitié-Salpêtrière Hospital and Sorbonne University - Pierre et Marie Curie Campus, Paris, France.
Published: November 23rd 2024 | Updated: November 23rd 2024

Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Megan Clowse, MD, MPH: Improving Disease and Reducing Corticosteroids in SLE With DZP
November 21st 2024

Megan Clowse, MD, MPH: Improving Disease and Reducing Corticosteroids in SLE With DZP

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Philip Conaghan, MBBS, PhD, director, National Institute for Health & Care Research Leeds Biomedical Research Centre, and professor, Musculoskeletal Medicine, University of Leeds
November 20th 2024

LEVI-04 Improved Outcomes in Knee Osteoarthritis Compared With Placebo

Victoria Johnson
Megan Clowse, MD, MPH, Associate Professor of Medicine, Associate Professor in Obstetrics and Gynecology, and Associate Professor in Population Health Sciences, and Chief of the Division of Rheumatology and Immunology, Duke University School of Medicine
November 19th 2024

DZP Improves Disease Activity and Reduces Corticosteroid Use in SLE

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.